Denise K. Nawrocki

TL;DR: Results are suggestive of an immunization strategy for humans that is centered on use of the adenovirus vector and in which existing adenavirus immunity may be overcome by combined immunization with adjuvanted DNA and adenvirus vector boosting.

TL;DR: Results indicate that Ad5 is stabilized by non-ionic surfactants and cryoprotectants as well as excipients known to inhibit free-radical oxidation, which should significantly enhance the utility of Ad5 as a vector for vaccines and gene therapy.

TL;DR: The DNA vaccine-elicited immune responses were weaker than those elicited by the Ad5 vaccine and highly variable; formulation with chemical adjuvants led to moderate increases in the levels of Gag-specific T cells.

TL;DR: Investigation of plasmid DNA vaccine formulations containing a nonionic triblock copolymer adjuvant and a cationic surfactant indicates that the addition of BAK to DNA/CRL1005 formulations leads to the formation of approximately 300 nm CRL 1005-BAK-DNA particles that enhance the cellular immune response in rhesus monkeys.

TL;DR: V116 as mentioned in this paper is an investigational 21-valent non-adjuvanted pneumococcal conjugate vaccine (PCV), which is individually conjugated to the nontoxic diphtheria toxoid CRM197 carrier protein.